The ASX has edged lower after Kevin Warsh’s Fed nomination triggered a sharp gold selloff, dragging miners down with it.
Imagion Biosystems has submitted an Investigational New drug Application with the US FDA for its MagSense imaging agent for breast cancer.
In the second chunky biotech raising so far this year, PYC Therapeutics is seeking $650 million via a placement and rights issue.
Optiscan has made key progress in the December quarter with multiple clinical studies advancing to support US FDA submissions planned for 2026.
Pivotal Metals has completed an ore sorting trial for its Horden Lake copper project in Canada, delivering a grade uplift and potentially improved economics.
